Expression vector of human AD4BP.
Alternative name | SET-0097_13 |
---|---|
Clone info. | Expression vector of human AD4BP. Expression was confirmed by Western blotting with anti-FLAG antibody. |
Comment | Derived from Sugano BC032501. PCR cloning, forward primer: gactattcgtacgacgagga; reverse primer: tcaagtctgcttggcttgca. |
Vector backbone | pCMV_S-FLAG (RDB05956) (Plasmid) |
Size of vector backbone | 5.5 kb |
Selectable markers | Amp^r (E. coli), Neo^r (mammalian cell) |
Growth conditions | 37C, LB+Amp |
Gene/insert name | Human SF-1; AD4BP cDNA |
Depositor|Developer | DNA Bank, | |
Remarks, protocol and/or map (pdf) | RDB06299.pdf |
---|
Please check terms and conditions set forth by the depositor, which are specified in the RIKEN BRC Catalog and/or Web Catalog.
Ordering forms | Order form [Credit Card Payment ![]() ![]() ![]() MTA, for use for not-for-profit academic purpose [Word ![]() ![]() MTA, for use for for-profit purpose [Word ![]() Please visit Information of Request for Distribution.[link] |
---|---|
Terms and conditions for distribution | The RECIPIENT agrees to describe RIKEN BRC as the source of the MATERIAL and cite Gene 200, 149-156, 1997 in any publication. Additional terms and conditions: Regrding pRc/CMV: a) The modified pRc/CMV, and their descendants (collectively, LIFE MATERIALS), should be used for pre-clinical/non-human, research use only. b) LIFE MATERIALS shall not be used for any commercial purposes. c) LIFE MATERIALS shall not be transferred beyond the specified recipient. d) Recipient must contact Thermo Fisher Scientific Inc. at outlicense@thermofisher.com for any desired use of LIFE MATERIALS beyond the scope of a) to c) above. |
必要書類 | 提供依頼書 ![]() ![]() 提供同意書 (MTA, 非営利学術目的用)[Word ![]() ![]() 提供同意書 (MTA, 営利目的用)[Word ![]() 手続きの概要は、「提供申込みについて[link]」をご覧ください。 |
---|---|
MTAに書く使用条件 | 発表に際し、理研BRCから入手したことを明記し、指定する文献(Gene, 200, 149-156 (1997))を引用すること。 付加的使用条件: pRc/CMVについて: a) The modified pRc/CMV, and their descendants (collectively, LIFE MATERIALS), should be used for pre-clinical/non-human, research use only. b) LIFE MATERIALS shall not be used for any commercial purposes. c) LIFE MATERIALS shall not be transferred beyond the specified recipient. d) Recipient must contact Thermo Fisher Scientific Inc. at outlicense@thermofisher.com for any desired use of LIFE MATERIALS beyond the scope of a) to c) above. |
Catalog # | Resource name | Shipping form | Fee |
---|---|---|---|
RDB06299 | pCMFlag_hsNR5A1 | DNA solution |
JPY 9,460 (not-for-profit academic purpose) JPY 18,920 (for-profit-research purpose) plus cost of shipping containers, dry ice (if required) and shipping charge |
Materials & Methods section:
The pCMFlag_hsNR5A1 was provided by the RIKEN BRC through the National BioResource Project of the MEXT, Japan (cat. RDB06299). |
Reference section:
Further references such as user reports and related articles (go to bottom)
RIKEN BRC has sequenced portions of this material for quality test.
Please review the QC test results indicated by icon as well as clone information before placing your order.
Test sheet | RDB12861_A4Iqp1-2.pdf ![]() |
---|
Nucleotide sequence of a portion of this resource (if available).
Primer: CMV_Forward (Pr0016) Region: CMV pro, T7 pro, FLAG, insert 5' Sequence file: RDB12861_A4Iqd.seq ![]() |
---|
>06299_12861_A4Iq_CMV-Foward_A04_01.ab1 1 NNNNNNNNNN NNNNNNNNNN NGNNNNNNNG GGCGGTAGGC GTGTACGGTG GGAGGTCTAT 61 ATAAGCAGAG CTCTCTGGCT AACTAGAGAA CCCACTGCTT ACTGGCTTAT CGAAATTAAT 121 ACGACTCACT ATAGGGAGAC CCAAGCTGAA TTCACCATGG ACTACAAGGA CGATGACGAT 181 AAGGCGGCCG ACTATTCGTA CGACGAGGAC CTGGACGAGC TGTGCCCCGT GTGCGGGGAC 241 AAGGTGTCCG GCTACCACTA CGGACTGCTC ACGTGTGAGA GCTGCAAGGG CTTCTTCAAG 301 CGCACGGTGC AGAACAACAA GCACTACACG TGCACCGAGA GCCAGAGCTG CAAGATCGAC 361 AAGACGCAGC GCAAGCGCTG TCCCTTCTGC CGCTTCCAGA AATGCCTGAC GGTGGGGATG 421 CGCCTGGAAG CCGTGCGCGC TGACCGTATG AGGGGTGGCC GGAACAAGTT TGGGCCGATG 481 TACAAGCGGG ACCGGGCCCT GAAACAGCAG AAGAAGGCAC AGATTCGGGC CAATGGCTTC 541 AAGCTGGAGA CAGGGCCCCC GATGGGGGTG CCCCCGCCGC CCCCTCCCGC ACCGGACTAC 601 GTGCTGCCTC CCAGCCTGCA TGGGCCTGAG CCCAAGGGCC TGGCCGCCGG TCCACCTGCT 661 GGGCCACTGG GCGACTTTGG GGCCCCAGCA CTGCCCATGG CCGTGCCCGG TGCCCACGGG 721 CCACTGGCTG GCTACCTCTA CCCTGCCTTT CCTGGCCGTG CCATCNAGTC TGANTACCCG 781 GANCCTTATG CCAGCCCCCC ACAGCCTGGG CTGCCGTACN GCTACCCAGA GCCCTTCTCT 841 GGANGGCCCN ACNNGCCTGA NCTCATCNTG CANCTGCTGC NGCTGGANCC NGATGANGAN 901 CANGNNNGGG NCCGCATCTT GGGNTGCCNG NNNNANCCNN CCAAAAGCCG CCCCNANCAN 961 NNNNNNGNNN TNNNNNNTNC TGNNNNNNAN NNNCNNANCN NANCNTTCNN NNNCNNNNNN 1021 NNNN // |
Primer: BGH_rev2 (Pr0606) Region: bGH p(A), SP6 pro, insert 3' Sequence file: RDB12861_A4Iqe.seq ![]() |
>06299_12861_B0CdS_BGH_rev2_D05_04_ABI08.ab1 1 NNNNNNNNNN NNNNNNNNNG GNNGNNGGGN NAACAACAGA TGGCTGGCAA CTAGAAGGCA 61 CAGTCGAGGC TGATCAGCGA GCTCTAGCAT TTAGGTGACA CTATAGAATA GGGCCCTCTA 121 GATGCATGCT CGAGCGGCCT CAAGTCTGCT TGGCTTGCAG CATTTCGATG AGCAGGTTGT 181 TGCGGGGCAT CTCGTTGCCC AGGTGCTTGT GGTACAGGTA CTCCTTGGCC TGCATGCTCA 241 GGGCCCGCAC CTCCACCAGG CACAGCAGCA GCTGCTGGAA TTTGTCCCCG CAGTGCGGGT 301 AGTGGCACAG GGTGTAGTCA AGCAGGGCGG CGTTGGCCTT CTCCTGAGCG TCTTTCACCA 361 GGATGTGGTT ATTCAGGAAC TTCAAATCCA GGCTGAAGAG GATGATGAAC TTGAGGCAGA 421 CAAACTCCTG CCGGTCCAGC TGCAGCGCAA GCAGCTGCAG CACCAGCTCC TGCGCCCGCA 481 ACACCAGGCT GTGCAGCAGC GAGCCCGCCT GGGTGGCCAC TGTGGTCAGC TCCACCTCCT 541 GCCCGGTGAC CAGCAGGATG CTGCCCTCCT TGCCGTGCTG GACCTGGCGG TAGATGTGGT 601 CGAACACCAG CAGCTCGCTC CAGCAGTTCT GCAGCAGCGT CATCTGGTCG GCCACCTCCA 661 GCTCCTTGAA GACCATGCAC CTGCGTGCCC AGTCCACGAT GGAGATGAAG GTCTGGTCGG 721 CCATTCTGCA CAGGANGCCG AANGCCGCCG GCTGGTCGGG GCGGCTTTTG GTGGGCTCCT 781 GCAGGCAGCC CAAGATGCGG GCCCGCACCT GGTCCTCATC CGGCTNCNGC TGCAGCAGCT 841 GCANGANGAN CTCNNNCACG TNGGGCCCTC CAGANAANNG NNTCTGGGTA NCCNTACGGC 901 AGCCCAGGCT GTGGGGGGCN NGNNTNANNN TNCNGGNANT CNNANTTGAT GGCNCNGNCC 961 NNNAAANNNN NGNNANNNNN NGNNNNNNNN NN // |
Primer: SV40pro_ori_F (Pr0731) Region: SV40 pro_ori, NeoR Sequence file: RDB12861_A4Iqf.seq ![]() |
>06299_12861_B0CdS_SV40pro_ori_F_E05_05_ABI08.ab1 1 NNNNNNNNNN NNNNNNNNNC NNCTCGNCCT CTGAGCTATT CNNGAAGTAG TGAGGAGGCT 61 TTTTTGGAGG CCTAGGCTTT TGCAAAAAGC TCCCGGGAGC TTGGATATCC ATTTTCGGAT 121 CTGATCAAGA GACAGGATGA GGATCGTTTC GCATGATTGA ACAAGATGGA TTGCACGCAG 181 GTTCTCCGGC CGCTTGNGNG GAGAGGCTAT TCGGCTATGA CTGGGCACAA CAGACAATCG 241 GCTGCTCTGA TGCCGCCGTG TTCCGGCTGT CAGCGCAGGG GCGCCCGGTT CTTTTTGTCA 301 AGACCGACCT GTCCGGTGCC CTGAATGAAC TGCAGGACGA GGCAGCGCGG CTATCGTGGC 361 TGGCCACGAC GGGCGTTCCT TGCGCAGCTG TGCTCGACGT TGTCACTGAA GCGGGAAGGG 421 ACTGGCTGCT ATTGGGCGAA GTGCCGGGGC AGGATCTCCT GTCATCTCAC CTTGCTCCTG 481 CCGAGAAAGT ATCCATCATG GCTGATGCAA TGCGGCGGCT GCATACGCTT GATCCGGCTA 541 CCTGCCCATT CGACCACCAA GCGAAACATC GCATCGAGCG AGCACGTACT CGGATGGAAG 601 CCGGTCTTGT CGATCAGGAT GATCTGGACG AAGAGCATCA GGGGCTCGCG CCAGCCGAAC 661 TGTTCGCCAG GCTCAAGGCG CGCATGCCCG ACGGCGAGGA TCTCGTCGTG ACCCATGGCG 721 ATGCCTGCTT GCCGAATATC ATGGTGGAAA ATGGCCGCTT TTCTGGATTC ATCGACTGTG 781 GCCGGCTGGG TGTGGCGGAN CGCTATCNNA CATAGCGTTG GCTANCCGTG ATATTGCTGA 841 AGANCTTGNN GGNNAANGGG CTNACCGCTT NCNCGTGCTT TACNGNATCG CCGCTCCCGA 901 NTCNNANCGC ATCGCCNTCN NTCNNNTNCT TGANNANTTN TNNTGANCNG NNNTNTGGGG 961 TTCNAAATGA NCGANCNAGC GNNNCCNNNN NTGNNNTCNN NNNNTTNNNA NNCNNNNNNN 1021 NNN // |
Please visit Sequencing and PCR primers for primer information.
Original, user report and related articles
user_report | Yamauchi, K., Overexpression of Nuclear Receptor 5A1 Induces and Maintains an Intermediate State of Conversion between Primed and Naive Pluripotency. Stem Cell Reports 14 (3): 506-519 (2020). PMID 32084386. [link to RRC of NBRP] |
---|---|
user_report | Matsuo, K., Significance of dopamine D1 receptor signalling for steroidogenic differentiation of human induced pluripotent stem cells. Sci. Rep. 7 (1): 15120 (2017). PMID 29123220. [link to RRC of NBRP] |
user_report | Sonoyama, T.,, Differentiation of human embryonic stem cells and human induced pluripotent stem cells into steroid-producing cells. Endocrinology, 153 (9): 4336-4345 (2012). PMID 22778223. [link to RRC of NBRP] |
Featured content